Prof. Donglin Wang 王东林
Chief Physician, Professor
Department of Medical Oncology, Chongqing University Cancer Hospital, Chongqing
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Chemotherapy and molecular targeted therapy for malignant tumors, with a focus on colorectal, lung, gastric, breast, and head and neck cancers.
Dr. Wang holds an MD and PhD from Third Military Medical University (graduated 1985; master’s 1990, doctorate 1994). Former roles include Deputy Director of the Oncology Center at Xinqiao Hospital, and Director of Oncology at Tongji Hospital (Tongji University) and Sichuan Provincial People’s Hospital. Dr. Wang has received seven National Natural Science Foundation grants and other funding, one military science and technology progress award, edited one book, and published over 50 papers.
Professional roles
- Vice Chair, Oncology Professional Committee, Chongqing Association of Integrative Traditional Chinese and Western Medicine
- Vice Chair, Targeted Therapy Professional Committee, Chongqing Anti-Cancer Association
- Vice Chair, Minimally Invasive and Interventional Therapy Professional Committee, Chongqing Association of Integrative Traditional Chinese and Western Medicine
Name order: in Chinese the family name comes first (Wang Donglin). Papers usually list the name as Donglin Wang or Wang D.
Selected publications
20 papers on PubMed matched by name and affiliation; 6 as first or senior author since 2016. Most recent first- or senior-author papers:
- Discov Oncol, 2026 (senior author): Therapeutic implications of peroxisome proliferator-activated receptors in non-small cell lung cancer. PubMed 42477175
- Adv Ther, 2019 (senior author): Maintenance Versus Intermittent Strategies in the Treatment of Metastatic Colorectal Cancer: A Meta-Analysis from Another Angle. PubMed 31432462
- Medicine (Baltimore), 2019 (senior author): Apatinib is effective as third-line and more treatment of advanced metastatic non-small-cell lung cancer: A retrospective analysis in a real-world setting. PubMed 31490378
- Medicine (Baltimore), 2019 (senior author): Pleural effusion as a substitute for tumor tissue in detecting EGFR/ALK mutations in non-small cell lung cancer: A systematic review and meta-analysis. PubMed 31045816
- Neural Regen Res, 2019 (senior author): Serum and cerebrospinal fluid tau protein level as biomarkers for evaluating acute spinal cord injury severity and motor function outcome. PubMed 30688276
- Onco Targets Ther, 2018 (senior author): The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective analysis. PubMed 29731642
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion